Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 15 2023 - 7:40AM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it has achieved positive results for its toxicology study of
SP-26, its novel time-released, dosage-controlled formulation of
ketamine. The study results evaluated the feasibility of using a
rising dose design or maximum feasibility.
In collaboration with Experimur, a Frontage Laboratories
company, Silo Pharma tested SP-26 in a toxicology and tolerability
study in mini pigs using an ascending (descending) dosing regimen.
The study utilized the bioanalytical methods required to perform
toxicology studies by the U.S. Food and Drug Administration (FDA)
in advance of initiating clinical studies for SP-26.
“Today’s positive results are an important step as we move
closer to achieving all needed components to plan human trials of
SP-26.” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
“We are advancing our work with our regulatory partners to
prepare a Pre-Investigational New Drug (IND) package for SP-26 and
intend to pursue the FDA’s streamlined 505(b)(2) regulatory pathway
for drug approval.”
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information
visit www.silopharma.com.
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as “may,” “will,” “expect,” “anticipate,”
“aim,” “estimate,” “intend,” “plan,” “believe,” “potential,”
“continue,” “is/are likely to” or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company’s filings with the SEC.
Contact800-705-0120
investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jul 2023 to Jul 2024